enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Atypical hyperplasia of the breast - Diagnosis and treatment ...

    www.mayoclinic.org/diseases-conditions/atypical...

    Treatment for atypical hyperplasia of the breast may involve surgery to remove the atypical cells. Not everyone needs surgery. Your healthcare team might recommend more-frequent breast cancer screening to watch for signs of breast cancer.

  3. Atypical Lobular Hyperplasia and Risk of Breast Cancer

    www.verywellhealth.com/atypical-lobular...

    How Is Atypical Lobular Hyperplasia Treated? Many cases of ALH do not require treatment and will instead be monitored regularly to check for any changes in breast tissues. This is called active surveillance.

  4. Atypical hyperplasia of the breast is defined as abnormal epithelial proliferative breast lesions that are not qualitatively or quantitatively abnormal enough to be classified as carcinoma in situ. Atypical hyperplasia is a premalignant condition and may occur in either ductal or lobular epithelium.

  5. Atypical Hyperplasia of the Breast — Risk Assessment and ...

    www.nejm.org/doi/full/10.1056/NEJMsr1407164

    In this report, we describe the histologic and molecular features of atypical hyperplasia, the current management of the condition, new data on the cumulative risk of breast cancer among women...

  6. Surgical management of ADH, ALH, and LCIS | ACS

    www.facs.org/for-medical-professionals/news...

    Appropriate surveillance and risk-reduction strategies for atypical ductal hyperplasia or lobular neoplasia are discussed.

  7. Diagnosis and Management of Benign, Atypical, and ...

    www.mayoclinicproceedings.org/article/s0025-6196...

    Atypical hyperplasia (AH) may present in biopsy material over a broad age range, averaging 48 to 52 years. Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) confer a similar degree of RR of breast cancer, approximately 4-fold increased risk compared with age-matched women.

  8. Clinicians should counsel women with atypical hyperplasia regarding risk-reducing strategies, which include preventive endocrine therapy options, enhanced surveillance imaging, and lifestyle modifications.